Hypertrophic scars (HS) are fibrotic skin disorders characterized by excessive fibroblast activity and collagen accumulation, frequently leading to aesthetic distortion and physical discomfort. While 5-fluorouracil (5-Fu) injection has been used clinically to suppress HS progression, its efficacy is often limited by rapid clearance and systemic side effects. To address the limitations of conventional 5-Fu therapy, we developed a near-infrared (NIR)-responsive dissolving microneedle (5FIPP MNs) system for localized and sustained drug delivery. The microneedle tips, composed of polyvinylpyrrolidone co-loaded with 5-Fu and indocyanine green (ICG), enable mechanical penetration into scar tissue and undergo photothermal-triggered separation upon NIR irradiation, leaving drug-loaded tips embedded intradermally for prolonged release. In vitro studies revealed that 5FIPP MNs effectively induce apoptosis and arrest cell cycle progression, thereby significantly inhibiting fibroblast proliferation, migration, and collagen synthesis. In vivo , the 5FIPP MNs enabled sustained 5-Fu release directly within scar tissue, leading to significantly greater scar regression than free 5-Fu, along with optimized Collagen I/III ratio, attenuated local inflammation, and minimal systemic exposure. This design reconciles the trade-off between insertion robustness and prolonged drug release observed in traditional microneedles. Our findings highlight the potential of this platform for efficient HS therapy and for treating other fibrotic skin conditions.